Leap Therapeutics, Inc. - LPTX STOCK NEWS

Leap Therapeutics (Nasdaq: LPTX) announced promising results from a Phase 1b/2a clinical trial of DKN-01 for advanced esophagogastric cancer presented at the SITC 2020 Annual Meeting. The study revealed that patients with high tumoral DKK1 expression had superior clinical outcomes, including doubled median progression-free survival (PFS) and better overall survival (OS) rates, as compared to those with low DKK1 levels. These findings suggest that DKK1 expression could serve as a predictive biomarker, supporting further studies combining DKN-01 with anti-PD-1 therapies.

Leap Therapeutics, a biotechnology company, will present crucial data on its DKN-01 monoclonal antibody for esophagogastric cancer at the Society of Immunotherapy of Cancer's (SITC) 35^th Annual Meeting, from November 9-14, 2020. Dr. Samuel J. Klempner will present findings that show DKK1 expression correlates with improved clinical outcomes in patients. DKN-01, recognized by the FDA with Orphan Drug and Fast Track designations, targets the Dickkopf-1 protein, crucial in tumor biology and immunosuppression.

Leap Therapeutics (Nasdaq:LPTX) announced that the FDA has granted Fast Track designation to its drug DKN-01 for treating gastric and gastroesophageal junction adenocarcinoma in patients whose tumors express high Dickkopf-1 (DKK1) protein after prior chemotherapy. This designation aims to expedite the drug's development and review, enabling faster access for patients with unmet medical needs. DKN-01 is also undergoing trials for various cancers and has received Orphan Drug Designation for gastric and gastroesophageal junction cancers.

Leap Therapeutics, a biotechnology firm listed on Nasdaq under LPTX, announced that its CEO, Douglas E. Onsi, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 3:00 p.m. Eastern Time. The presentation will be available via webcast on the company's Investors page. Leap is focused on developing targeted immuno-oncology therapeutics, with its leading candidate, DKN-01, in trials for various cancers.

Leap Therapeutics (Nasdaq: LPTX) has announced the expansion of its leadership team, appointing Jason S. Baum as Vice President, Head of Translational Medicine, and Christine M. Granfield as Vice President, Head of Regulatory Affairs and Quality. These appointments bring over 37 years of combined industry experience, with Baum's expertise in precision medicine and Granfield's extensive regulatory background expected to enhance Leap's development of its lead candidate, DKN-01, targeting various cancers. The company focuses on advancing innovative therapeutics in oncology.

Leap Therapeutics, Inc. (Nasdaq:LPTX) reported its Q2 2020 financial results, highlighting a net loss of $6.5 million, down from $8.4 million in Q2 2019. The company completed a $51.75 million public offering and presented positive DKN-01 clinical trial data, showing responses in endometrial and carcinosarcoma patients. DKN-01 received Orphan Drug Designation for gastric and gastroesophageal junction cancers, enhancing its development prospects. Cash and marketable securities stood at $64.9 million as of June 30, 2020.

Leap Therapeutics (NASDAQ: LPTX) announced the closing of an additional 3,375,000 shares in a public offering, resulting in approximately $51.75 million in gross proceeds. This follows the underwriters' full exercise of their option to purchase additional shares. The offering was managed by Piper Sandler & Co. and Raymond James & Associates, among others. Leap focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as its leading candidate in clinical trials for multiple cancer types.

Leap Therapeutics, Inc. (NASDAQ:LPTX) has successfully closed a public offering of 20,250,000 shares of common stock and pre-funded warrants for an estimated gross amount of $45 million. The offering, managed by Piper Sandler & Co. and Raymond James & Associates, utilized an effective shelf registration statement previously filed with the SEC. These funds will support Leap's development of targeted and immuno-oncology therapeutics, particularly its lead candidate DKN-01, currently in clinical trials for various cancers. Detailed offering materials are available on the SEC website.

Leap Therapeutics (NASDAQ:LPTX) announced the pricing of a public offering of common stock at $2.00 per share and pre-funded warrants at $1.999 each, aiming to raise approximately $45 million before expenses. The offering is expected to close around June 22, 2020. Proceeds will fund the development of DKN-01, manufacturing of clinical trial materials, and general corporate purposes. The offering is being managed by Piper Sandler & Co. and Raymond James Associates, Inc., with an option for underwriters to purchase an additional 3,375,000 shares.